NASDAQ:IBB iShares Biotechnology ETF (IBB) Price, Holdings, & News → [Urgent] Protect your money before November (From Weiss Ratings) (Ad) Free IBB Stock Alerts $134.38 -1.06 (-0.78%) (As of 06/18/2024 ET) Add Compare Share Share Today's Range$134.27▼$135.7650-Day Range$124.64▼$138.0652-Week Range$111.83▼$141.16Volume922,073 shsAverage Volume1.67 million shsMarket Capitalization$7.28 billionAssets Under Management$7.38 billionDividend Yield0.30%Net Expense Ratio0.45% Stock AnalysisStock AnalysisChartDividendHeadlinesHoldingsOptions ChainOwnershipRatingsSEC FilingsShort InterestTrendsStock AnalysisChartDividendHeadlinesHoldingsOptions ChainOwnershipRatingsSEC FilingsShort InterestTrends Get iShares Biotechnology ETF alerts: Email Address About iShares Biotechnology ETF (NASDAQ:IBB)iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. Due to the use of representative sampling, the Fund may or may not hold all of the securities that are included in the Index. The Fund’s investment advisor is BlackRock Fund Advisors, which is indirectly owned by BlackRock, Inc.Read More IBB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IBB ETF News HeadlinesMay 29, 2024 | investing.comTransportation Stocks Are Selling Off Without a CatalystMay 27, 2024 | investing.comSemiconductors Shine, But Outlook for Other Sectors Remains MixedJune 19, 2024 | Weiss Ratings (Ad)[Urgent] Protect your money before NovemberThose who listened to his warnings could have kept their money safe and even made substantial profits during each crisis. In fact, the Wall Street Journal reported that his work was more accurate … and more profitable than that of … Deutsche Bank … Merrill Lynch … JPMorgan Chase … Goldman Sachs … and every other firm reviewed.May 24, 2024 | investorplace.comWhy the Rest of 2024 Could Be Good for Investing in Biotech StocksMay 10, 2024 | seekingalpha.comIGV: The Software ETF Will Eventually Share In The Love We're Now Giving To SemiconductorsMay 2, 2024 | investing.comRisk On, Risk Off, or Risk Who Knows?May 1, 2024 | investing.comWhen Silver Looks Bad, It’s Usually a Sign of a BottomApril 30, 2024 | markets.businessinsider.comApril Showers On Wall Street: Miners, Utilities Emerge As Bright Spots In Gloomy MarketJune 19, 2024 | Weiss Ratings (Ad)[Urgent] Protect your money before NovemberThose who listened to his warnings could have kept their money safe and even made substantial profits during each crisis. In fact, the Wall Street Journal reported that his work was more accurate … and more profitable than that of … Deutsche Bank … Merrill Lynch … JPMorgan Chase … Goldman Sachs … and every other firm reviewed.April 28, 2024 | nasdaq.comJune 7th Options Now Available For iShares Trust - iShares Biotechnology ETF (IBB)See More Headlines Receive IBB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for iShares Biotechnology ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address Fund Details IssueriShares Fund NameiShares Biotechnology ETF Tax ClassificationRegulated Investment Company Stock ExchangeNASDAQCurrent SymbolNASDAQ:IBB Inception Date2/5/2001 Fund ManagerDiane Hsiung, Jennifer Hsui, Greg Savage, Alan Mason WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkICE Biotechnology Index (TR) (USD) CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings220 Fund Statistics Assets Under Management$7.38 billion Average Daily Volume$1.30 million Discount/Premium0.04% Administrator, Advisor and Custodian AdministratorJPMorgan Chase Bank, N.A. AdvisorBlackRock Fund Advisors CustodianJPMorgan Chase Bank, N.A. DistributorBlackRock Investments, LLC Transfer AgentJPMorgan Chase Bank, N.A. TrusteeN/A Lead Market MakerLatour Trading Options OptionableOptionable Options Volume2,047 Put Options1,011 Call Options1,036 Short Interest8,740,000 shs Miscellaneous Outstanding Shares54,200,000Beta0.75 Creation Unit50,000 Creation Fee$614.00 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Ad Weiss Ratings[Urgent] Protect your money before NovemberThose who listened to his warnings could have kept their money safe and even made substantial profits during each crisis. In fact, the Wall Street Journal reported that his work was more accurate … and more profitable than that of … Deutsche Bank … Merrill Lynch … JPMorgan Chase … Goldman Sachs … and every other firm reviewed.Click here to watch now. iShares Biotechnology ETF ExpensesTypeIBBHealth Care ETFsEquity ETFsNASDAQ ETFsAll ETFsManagement Fee0.45%0.56%0.54%0.47%0.51%Other Expenses0.00%0.33%0.50%0.39%0.54%Total Expense0.45%0.70%0.70%0.60%0.71%Fee Waiver0.00%-0.45%-0.55%-0.32%-0.60%Net Expense0.45%0.61%0.60%0.54%0.58% iShares Biotechnology ETF (IBB) Holdings & ExposureTop 10 IBB HoldingsVertex Pharmaceuticals(NASDAQ:VRTX)Holding Weight: 9.30%Amgen(NASDAQ:AMGN)Holding Weight: 8.99%Regeneron Pharmaceuticals(NASDAQ:REGN)Holding Weight: 8.34%Gilead Sciences(NASDAQ:GILD)Holding Weight: 7.13%Moderna(NASDAQ:MRNA)Holding Weight: 5.09%IQVIA(NYSE:IQV)Holding Weight: 3.88%Biogen(NASDAQ:BIIB)Holding Weight: 3.28%Mettler-Toledo International(NYSE:MTD)Holding Weight: 2.98%BioNTech(NASDAQ:BNTX)Holding Weight: 2.06%argenx(NASDAQ:ARGX)Holding Weight: 1.90%IBB Sector ExposureIBB Industry ExposureFull Holdings Details Key ExecutivesGeorge G. C. Parker Ph.D.Independent Chairman of the Board of TrusteesMichael Arthur LathamPresident, TrusteeJack GeeChief Financial Officer, TreasurerGeoffrey D. FlynnChief Operating Officer, Executive Vice PresidentBio & Compensation - Amy SchioldagerExecutive Vice PresidentIra P. ShapiroVice President, Chief Legal OfficerMatt TuckerVice PresidentBio & Compensation - Eilleen M. ClavereSecretaryCecilia H. HerbertIndependent TrusteeCharles A. HurtyIndependent TrusteeMore ExecutivesSimilar ETFsVanEck Pharmaceutical ETFNASDAQ:PPHVanEck Biotech ETFNASDAQ:BBHInvesco S&P SmallCap Health Care ETFNASDAQ:PSCHInvesco Dorsey Wright Healthcare Momentum ETFNASDAQ:PTHProShares Ultra Nasdaq BiotechnologyNASDAQ:BIBInstitutional OwnershipEverSource Wealth Advisors LLCSold 465 shares on 6/11/2024Ownership: 0.006%Objective Capital Management LLCBought 101 shares on 6/5/2024Ownership: 0.005%Cambridge Trust Co.Sold 207 shares on 5/30/2024Ownership: 0.001%Cetera Investment AdvisersBought 79,541 shares on 5/24/2024Ownership: 0.172%Cetera Advisors LLCBought 32,025 shares on 5/24/2024Ownership: 0.084%View All Institutional Transactions IBB ETF - Frequently Asked Questions How have IBB shares performed in 2024? iShares Biotechnology ETF's stock was trading at $135.85 at the beginning of 2024. Since then, IBB stock has decreased by 1.1% and is now trading at $134.38. View the best growth stocks for 2024 here. How often does iShares Biotechnology ETF pay dividends? What is the dividend yield for iShares Biotechnology ETF? iShares Biotechnology ETF declared a quarterly dividend on Wednesday, March 20th. Shareholders of record on Friday, March 22nd will be given a dividend of $0.126 per share on Wednesday, March 27th. This represents a $0.50 dividend on an annualized basis and a yield of 0.38%. The ex-dividend date of this dividend is Thursday, March 21st. Read our dividend analysis for IBB. What does IBB invest in? iShares Biotechnology ETF is a equity fund issued by iShares. IBB focuses on health care investments and follows the ICE Biotechnology Index (TR) (USD). The fund's investments total to approximately $7.38 billion assets under management. What stocks does iShares Biotechnology ETF hold? IBB invests in 220 holdings. Some of the stocks in their portfolio include Vertex Pharmaceuticals (VRTX), Amgen (AMGN), Regeneron Pharmaceuticals (REGN), Gilead Sciences (GILD), Moderna (MRNA), IQVIA (IQV), Biogen (BIIB), Mettler-Toledo International (MTD), BioNTech (BNTX) and argenx (ARGX). What is the management fee for iShares Biotechnology ETF? iShares Biotechnology ETF's management fee is 0.45% and has no other recorded expenses or fee waivers. The net expense ratio for IBB is 0.45%. When did iShares Biotechnology ETF's stock split? iShares Biotechnology ETF's stock split on Friday, December 1st 2017. The 3-1 split was announced on Tuesday, November 7th 2017. The newly minted shares were issued to shareholders after the market closes on Thursday, November 30th 2017. An investor that had 100 shares of stock prior to the split would have 300 shares after the split. What other stocks do shareholders of iShares Biotechnology ETF own? Based on aggregate information from My MarketBeat watchlists, some companies that other iShares Biotechnology ETF investors own include NVIDIA (NVDA), Walt Disney (DIS), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Cisco Systems (CSCO), Micron Technology (MU), Bank of America (BAC), Johnson & Johnson (JNJ) and PayPal (PYPL). Who are iShares Biotechnology ETF's major shareholders? iShares Biotechnology ETF's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Farallon Capital Management LLC (0.00%), BNP Paribas Financial Markets (3.70%), Commerce Bank (1.31%), Global Assets Advisory LLC (0.87%), Commonwealth Equity Services LLC (0.36%) and Raymond James & Associates (0.33%). How do I buy shares of iShares Biotechnology ETF? Shares of IBB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IBB) was last updated on 6/19/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | SponsoredHistoric NVIDIA partnership could send this tiny AI stock soaring...After striking partnerships with trillion-dollar chipmaker NVIDIA... ARM surged over 60% in a week... Who's...Behind the Markets | SponsoredElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...Paradigm Press | SponsoredBill Clinton Backing Biden Replacement???Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be...The Freeport Society | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredWho are Nvidia’s Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredThe biggest lie in America unravels…Americans have been fed an insidious lie for decades. Fortunately, it's starting to unravel – and a few powerf...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iShares Biotechnology ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share iShares Biotechnology ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
